Endocrine Abstracts

Purpose: To describe pre- to post-treatment changes in clinical activity score (CAS) in patients with Graves orbitopathy treated with tocilizumab (TCZ).Introduction: Graves’ ophthalmopathy (GO) is an autoimmune disorder that affects 30-50% of patients with Graves’ disease. The first-line treatment of moderate to severe GO according to EUGOGO is intravenous glucocorticoids, but 20-30% of the cases appear to be corticosteroid refractory. Steroid-...